Los Angeles, CA-based NeuroSigma (NSIG) is set for its IPO of 3.6M shares of common stock at $13 - 15. The commercial stage life sciences firm develops bioelectric products based on external trigeminal nerve stimulation (TNS) to treat neurological and neuropsychiatric disorders such as epilepsy and depression. Its lead product is the Monarch eTNS system which is currently approved in the European Union as adjunctive treatment for epilepsy, in Canada for the treatment of drug-resistant epilepsy and in Australia for adjunctive treatment of drug-resistant epilepsy. A portion of the proceeds from the IPO will fund the Phase 3 trial to support a regulatory submission in the U.S. Financial results for 2013: Revenues: $35.8M; COGS: $47.9M; Gross Profit: ($12.1M); Operating Expenses: $6.2M (+8.6%); Net Loss: ($5.8M) (-11.9%); Loss Per Share: ($0.83) (-18.6%); Cash Burn Ops: ($2.6M) (-20.1%). Financial results for 1H 2014: Revenues: $23.9M (+195.1%); COGS: $12.1M) (+348.1%); Gross Profit: $11.8M (+118.5%); Operating Expenses: $6.9M (+153.9%); Net Loss: ($7.5M) (-205.4%); Loss Per Share: ($1.12) (-229.4%); Cash Burn Ops: ($2.1M) (-82.4%). S-1 ETFs: IBB, BIB, BIS Share this with a colleague
See the original post:
NeuroSigma on deck for IPO